X

Trial Profile

An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
Indications Bladder cancer; Carcinoma; Renal cancer; Solid tumours; Ureteral neoplasms; Urogenital cancer
Focus Adverse reactions; Registrational
Acronyms STRONG
Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

21 Dec 2022 Status changed from active, no longer recruiting to completed.
18 Nov 2022 Planned End Date changed from 31 Aug 2022 to 5 Dec 2022.
17 Nov 2022 This trial has been completed in Germany, according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com